1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
FDC Ltd.

FDC Ltd.

340.20
INR
+0.60
(+0.18%)
17.99EPS
23.56P/E
69.03BMarket Cap
Oct 27Next Earn
FDC Ltd.
BSE:FDC
(Bombay Stock Exchange)

Recent

price

340.20

P/E

ratio

23.56

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
38.23
38.49
42.16
47.09
49.78
55.53
56.61
59.8
62.06
77.63
77.84
90.24
106.96
117.84
129.14
132.85
134.71
Revenue per Share
8.11
7.3
8.51
7.59
8.33
9.48
10.6
9.76
9.74
13.94
17.73
12.82
11.67
18.59
16.39
17.29
17.99
Basic EPS, GAAP
5.38
6.26
6.94
-0.08
4.25
-7.54
7.22
6.35
4
12.74
8.5
1.72
2.52
7.76
13.56
0.85
- -
Free Cash Flow per Basic Share
1.75
2
2.01
2.24
2.25
5.42
- -
2.71
- -
0.8
- -
- -
0.01
0.01
4.98
4.98
- -
Dividend per Share
33.4
38.02
43.37
47.53
56.77
60.87
71.43
73.17
82.87
90.51
102.73
115.92
119.47
128.81
140.11
152.64
- -
Book Value per Share
32.96
37.56
43.15
47.37
56.65
60.65
70.87
72.71
82.5
90.14
102.47
115.64
119.13
128.55
139.85
152.4
- -
Tangible Book Value per Share
186
184
182
178
178
178
178
178
174
172
170
169
166
164
163
163
163
Basic Weighted Avg Shares
7,117
7,074
7,691
8,397
8,853
9,874
10,066
10,633
10,824
13,356
13,231
15,233
17,778
19,352
21,026
21,629
21,902
Sales/Revenue/Turnover
20.94
21.02
19.91
21.68
18.11
19.78
20.75
18.62
18.27
21
22.39
14.23
11.94
15.43
12.9
13.26
12.6
Operating Margin (%)
174
184
279
249
388
337
346
351
332
375
378
373
389
399
537
592
595
Depreciation Expense
1,509
1,341
1,552
1,353
1,481
1,687
1,885
1,735
1,698
2,399
3,013
2,164
1,940
3,052
2,668
2,814
2,926
Net Income, GAAP
13.96
22.13
21.52
38.03
27.26
27.34
25.13
27.89
28.25
25.03
22.32
25.3
24.82
23.01
25.31
24.87
24.89
Effective Tax Rate (%)
21.2
18.96
20.18
16.12
16.73
17.08
18.73
16.32
15.69
17.96
22.77
14.21
10.91
15.77
12.69
13.01
13.36
Profit Margin (%)
3,234
3,071
2,569
2,563
3,811
3,599
5,289
5,109
5,609
6,808
7,303
7,280
7,153
7,559
7,271
7,684
- -
Working Capital
25
20
15
11
9
8
7
6
5
96
75
253
208
126
121
106
- -
LT Debt
6,164
6,954
7,842
8,453
10,096
10,825
12,702
12,761
14,452
15,474
17,340
19,564
19,814
20,972
22,811
24,851
- -
Total Equity
22.25
17.28
16.55
13.83
12.51
13.58
12.84
10.75
10.26
14.73
13.73
8.84
7.97
11.28
9.3
9.08
- -
Return on Invested Capital (%)
26.42
20.46
20.99
16.75
16.06
16.18
16.08
13.68
12.53
16.1
18.34
11.69
9.85
14.93
12.2
11.85
- -
Return on Capital (%)
26.4
20.44
20.97
16.61
15.97
16.12
16.03
13.63
12.48
16.03
18.37
11.73
9.85
14.96
12.19
11.81
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
49
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
106
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
163
163
Market Capitalization
68,918
52,295
69,031

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
11,325
- -
Cash, Cash Equivalents & STI
- -
5,215
- -
Accounts Receivable, Net
- -
1,517
- -
Inventories
- -
3,553
- -
Total Current Liabilities
- -
3,641
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
49
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.78%
7.53%
8.94%
Free Cash Flow
8.24%
29.61%
-93.71%
Net Income, GAAP
8.02%
2.33%
5.49%
Sales/Revenue/Turnover
8.41%
10.44%
2.87%
Total Cash Common Dividend
- -
- -
-0.13%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6,383
5,138
4,641
4,919
21,026
2026
6,484
4,730
4,647
5,848
21,629
2027
6,677
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7.31
4.43
2.28
2.38
16.39
2026
7.45
1.75
1.74
6.35
17.29
2027
8.14
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4.98
2026
- -
- -
- -
- -
4.98
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
FDC Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients in India and over 50 countries worldwide, including the United States, United Kingdom, South Africa, and various markets in Latin America, Africa, Asia, and Europe; its core products encompass specialized formulations for anti-infectives such as Zifi, Zathrin, and Zoxan; oral rehydration salts including Electral and Electral-Z; electrolyte drinks like Enerzal; ophthalmics such as Iotim, Zoxan eye drops, and Dorzolamide combinations; anti-fungals including Zocon; anti-diabetics and anti-hypertensives like Amodep AT; vitamins, minerals, and nutraceuticals such as Vitcofol and Simyl-MCT Oil; alongside offerings in gastrointestinal, respiratory, gynaecology, dermatology, analgesics, anti-coagulants, anti-ulcerants, and critincare therapies like steroids and antibiotics in tablets, capsules, powders, liquids, injectables, creams, and eye/ear drops. Founded in 1936 and headquartered in Mumbai, India, the company operates manufacturing facilities in Maharashtra, Goa, Waluj, Sinnar, Baddi, and Himachal Pradesh that hold certifications from US-FDA, UK-MHRA, WHO-GMP, and other global regulators, targeting healthcare providers, hospitals, and consumers across therapeutic segments with a focus on accessible, affordable quality products. In recent developments, FDC reported consolidated revenues of Rs 21,988 million for FY25, up 7.5% year-over-year, alongside unaudited financial results for quarters ended September 30, 2024, and December 31, 2024, declared its first interim dividend for FY25, approved the re-appointment of Executive Director Ashok Anand Chandavarkar for five years effective March 1, 2026, and continues expanding its global exports with over 300 products reaching diverse markets.